Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

XNW27011

PreclinicalSmall molecule

EEvopoint Biosciences Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic Adenocarcinoma MetastaticActive, not recruiting

Pancreatic Adenocarcinoma MetastaticPreclinical

Active, not recruiting

Timeline

Expected Milestones

Q2 2027

PreclinicalActive, not recruiting

Pancreatic Adenocarcinoma Metastatic

NCT06792435

Clinical

Trials by Indication[1]

Pancreatic Adenocarcinoma Metastatic1 trial

A Phase I/Ⅱ, First-in-Human Study of XNW27011 in Patients With Locally Advanced and/or Metastatic Solid Tumors

Active, not recruiting·EEvopoint Biosciences Inc.·Preclinical·NCT06792435·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for XNW27011. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — XNW27011 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for XNW27011. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Evopoint Biosciences Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: EEvopoint Biosciences Inc.

Related News